American Healthcare REIT vs Sabra Health Care REIT
AHR and SBRA side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AHR and SBRA compare
American Healthcare REIT is the larger company, worth 2.3 times as much as Sabra Health Care REIT ($11.7B against $5.0B).
On earnings, Sabra Health Care REIT is cheaper: it trades at 75.9× trailing earnings, against 78.7× for American Healthcare REIT.
Sabra Health Care REIT grew revenue faster over the last twelve months (17.3% versus 16.4% for American Healthcare REIT).
Sabra Health Care REIT keeps more of each dollar of sales as profit, with a net margin of 7.6% compared with 4.8% at American Healthcare REIT.
Both pay dividends: American Healthcare REIT yields 1.9% and Sabra Health Care REIT 6.1%.
American Healthcare REIT scores higher on the StockData Score (11 against 7 for Sabra Health Care REIT), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AHR | SBRA |
|---|---|---|
| Size and price | ||
| Market cap | $11.7B | $5.0B |
| Share price | $53.52 | $19.74 |
| Change, 1 year | 20.1% | 14.6% |
| Change, 5 years | – | 32.2% |
| Beta (5Y) | 0.49 | 0.48 |
| Employees | 121 | 58 |
| StockData Score | ||
| Total score | 11 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 2 |
| Performance score | 4 (better) | 2 |
| Health score | 2 (better) | 0 |
| Dividend score | 1 | 3 (better) |
| Valuation | ||
| P/E | 78.7× | 75.9× (better) |
| P/S | 4.7× (better) | 5.9× |
| P/B | 3.2× | 1.8× (better) |
| EV/EBITDA | 16.0× | 12.5× (better) |
| Fair value | $23.17 | $12.68 |
| Margin of safety | −131% | −55.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 16.4% | 17.3% (better) |
| Revenue growth, 5Y average | 16.2% (better) | 5.3% |
| Net income growth (TTM) | – | −64.1% |
| EPS growth (TTM) | – | −65.8% |
| EPS growth, 5Y average | 53.1% (better) | −0.91% |
| Profitability | ||
| Gross margin | 21.2% | – |
| Operating margin | 19.2% | – |
| Net margin | 4.8% | 7.6% (better) |
| Return on equity | 4.0% (better) | 2.4% |
| Return on invested capital | 16.5% | – |
| Financial health | ||
| Interest coverage | 6.2× | – |
| Altman Z-score | 3.89 (better) | 1.25 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 1.9% | 6.1% (better) |
| Payout ratio | 148% | 455% |
| Years of dividend growth | 0 | 0 |
| Dividend growth, 5Y average | 3.1% (better) | −2.3% |
| Buyback yield | −11.5% | – |
| Shareholder yield | −9.6% | 6.1% (better) |
| Ownership | ||
| Held by institutions | 103% | 102% |
| Held by insiders | 0.63% | 1.9% |
| Insider net buying, 12 months | −$5.5M | −$4.5M (better) |
| Short interest, % of float | 14.7% | 7.9% |
Go deeper
- AHR stock overview
- AHR income statement
- AHR valuation and score
- SBRA stock overview
- SBRA income statement
- SBRA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.